Moderna: Pandemic Overlooked, Stealth Buy
This is a Moderna news story, published by Yahoo Finance, that relates primarily to Moderna news.
Moderna news
For more Moderna news, you can click here:
more Moderna newsModerna news
For more Moderna news, you can click here:
more Moderna newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
biotech Moderna. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest only other Moderna vaccine news, stocks news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
best stocksThe Motley Fool
•Health
Health
Down 36%, Is Moderna a Buy on the Dip?
71% Informative
Biotech Moderna 's Spikevax coronavirus vaccine received emergency use authorization ( EUA ) from the U.S. Food and Drug Administration ( FDA ) The company's stock is down a headache-inducing 36% year to date , compared to the S&P 500 index's mere 9% slide.
Moderna has been diligently plugging away since its founding on exploring uses for the messenger RNA (mRNA) based technology that drives its vaccine.
It's harnessing this to develop vaccines for an admirably wide range of disorders.
Stock Advisor’s total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500.
Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
The Motley Fool recommends BioNTech Se and Moderna .
VR Score
67
Informative language
65
Neutral language
4
Article tone
semi-formal
Language
English
Language complexity
45
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links